Clinical Trial Detail

NCT ID NCT04150562
Title Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

clear cell renal cell carcinoma

Therapies

Avelumab + rhIL-15

Age Groups: adult senior

No variant requirements are available.